In patients with ≥5% PD-L1 expression,
the median PFS was 4.2 months with Opdivo and 5.9 months with platinum-based doublet chemotherapy
(stratified hazard ratio [HR]=1.15 [95% CI: 0.91, 1.45, p=0.25]).